- Home
- IOVA vs IBTA Comparison
IOVA vs IBTA Comparison
Compare IOVA & IBTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- IBTA
- Stock Information
- Founded
- IOVA 2007
- IBTA 2011
- Country
- IOVA United States
- IBTA United States
- Employees
- IOVA N/A
- IBTA N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- IBTA
- Sector
- IOVA Health Care
- IBTA
- Exchange
- IOVA Nasdaq
- IBTA Nasdaq
- Market Cap
- IOVA 975.1M
- IBTA 892.4M
- IPO Year
- IOVA N/A
- IBTA 2024
- Fundamental
- Price
- IOVA $2.69
- IBTA $27.38
- Analyst Decision
- IOVA Buy
- IBTA Hold
- Analyst Count
- IOVA 11
- IBTA 10
- Target Price
- IOVA $11.90
- IBTA $44.33
- AVG Volume (30 Days)
- IOVA 16.7M
- IBTA 826.4K
- Earning Date
- IOVA 08-07-2025
- IBTA 08-13-2025
- Dividend Yield
- IOVA N/A
- IBTA N/A
- EPS Growth
- IOVA N/A
- IBTA 2512.20
- EPS
- IOVA N/A
- IBTA 2.84
- Revenue
- IOVA $241,525,000.00
- IBTA $367,604,000.00
- Revenue This Year
- IOVA $86.62
- IBTA $6.62
- Revenue Next Year
- IOVA $69.13
- IBTA $15.30
- P/E Ratio
- IOVA N/A
- IBTA $9.64
- Revenue Growth
- IOVA 636.99
- IBTA 3.49
- 52 Week Low
- IOVA $1.64
- IBTA $22.50
- 52 Week High
- IOVA $12.51
- IBTA $79.80
- Technical
- Relative Strength Index (RSI)
- IOVA 54.92
- IBTA 35.20
- Support Level
- IOVA $2.44
- IBTA $22.50
- Resistance Level
- IOVA $2.85
- IBTA $27.65
- Average True Range (ATR)
- IOVA 0.24
- IBTA 1.67
- MACD
- IOVA -0.00
- IBTA -0.36
- Stochastic Oscillator
- IOVA 83.16
- IBTA 34.37
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).